Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions
Brief Summary: The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated subjects.


Options:
A: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Vitamin K Antagonist; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin K antagonist | Arm Label: Acetylsalicylic acid film coated tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Arm Label: Placebo matching Acetylsalicylic acid film coated tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Acetylsalicylic acid placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: vitamin K antagonist; Assigned to Arm(s): Vitamin K Antagonist | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylsalicylic acid film coated tablet | Intervention Type: OTHER; Name: Acetylsalicylic acid placebo; Assigned to Arm(s): Placebo matching Acetylsalicylic acid film coated tablet
B: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
C: Arm Label: 12m DAPT Study Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo & Aspirin | Arm Label: 30m DAPT Study Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin | Intervention Type: DRUG; Name: Placebo & Aspirin; Assigned to Arm(s): 12m DAPT Study Arm | Intervention Type: DRUG; Name: Clopidogrel & Aspirin, Prasugrel & Aspirin; Assigned to Arm(s): 30m DAPT Study Arm
D: Arm Label: Stratum 1/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Clopidogrel | Arm Label: Stratum 1/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Clopidogrel | Arm Label: Stratum 2/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Ticagrelor | Arm Label: Stratum 2/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Stratum 1/ASA, Stratum 2/ASA | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Stratum 1/Rivaroxaban, Stratum 2/Rivaroxaban | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Stratum 1/ASA, Stratum 1/Rivaroxaban | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Stratum 2/ASA, Stratum 2/Rivaroxaban

Answer: C